I am expecting big things for this Company around early to mid November !!!!!!!!
I will send my proxy as Melbourne is a bit too far from Perth.
LETTER FROM THE CHAIRMAN Dear Shareholder It gives me great pleasure to report on a positive close to what has been a challenging 12 months for Consegna. Pleasingly, the turnaround of the company has put us in a position where we will start the new financial year with a renewed focus and a solid strategy to develop products in the respiratory and breathing management space. The final step in this new direction is the implementation of a new corporate brand, Rhinomed Limited. As you would recognise, Rhinology is the area of medicine that concerns itself with the nose. We believe Rhinomed is a brand that better articulates the opportunities and the markets we are pursuing. In February, we instituted a change in the Board structure and Management team. This included the appointment of Michael Johnson as CEO. Working closely with the board, he has put in place a systematic approach to tackling the core issues that has resulted in an improvement in shareholder value and the rapid progression of our commercialisation program for our main asset, the BreatheAssist™ technology platform. The Company’s core focus is the development and commercialisation of the BreatheAssist platform. The first product, the Turbine™ is being launched into the global sports market later this calendar year. Since February, we have made significant advances towards this goal and this is now reflected in the new product design and the disruptive branding and creative marketing campaign that will drive the launch of the Turbine™. These activities have been underpinned by a tight fiscal management plan and complemented by the execution of a manufacturing agreement with our manufacturing partner that will deliver long-term benefits to the Company. We will continue to leverage the adoption and acceptance we achieve in the sport and exercise markets through the introduction of a range of new high value solutions in sleep and snoring, follow this with a suite of products targeting the general wellbeing market and continue the development of the drug delivery program. Our ability to adapt our core technology platform and tap into these high value consumer, medical and health markets will position the Company for long and sustained growth. I would like to take this opportunity to thank the board and management team for their efforts in effecting the turnaround of the company. These endeavours are never undertaken lightly, however, the single-minded focus on delivering a return to shareholders has resulted in the development of a strategy that will deliver an exciting future for the company. Thank you for your continued support and we look forward to a productive 2014 as Rhinomed Limited. Martin Rogers, Chairman
CGP Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held
